Announcement on Convening the Q3 2026 Performance Briefing
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
Filed with SSE · Stock code 688513 ·
6ix is reading this filing.
View original source (Shanghai Stock Exchange)Chengdu Easton Biopharmaceuticals Co., Ltd. on 6ix
Story so far
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Receipt of Drug Registration Certificate for Ponatinib Tablets
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Vitamin K1 Injection
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026
Earlier from Chengdu Easton Biopharmaceuticals
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Receipt of Drug Registration Certificate for Ponatinib Tablets
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Vitamin K1 Injection
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026
- Announcement on Closure of Certain Special Accounts for Raised Funds
- Announcement on Voluntary Disclosure of Progress of Phase I Clinical Trials for EP-0226 Tablets
Follow Chengdu Easton Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Easton Biopharmaceuticals